There is plenty of stock for sale. If you are bidding less than the ASK, then you'll need to wait until someone wants to unload at your BID.
A Mid-Summer Review of Medizone Activities
August 10, 2015
We have observed that our AsepticSure project for hospital room disinfection has moved into a new phase of acceptance among a growing group of medical professionals. This signals both a critical and monumental shift, tilting us increasingly towards commercial success and global recognition for achieving a standard of disinfection that prior to AsepticSure was simply impossible.
In general, I believe shareholders accepted the reality of AsepticSure's ability to achieve greater than 6-log kill of infective pathogens in a health care setting - and the positive implications for health care - far sooner than the medical professionals. Why? The world of science and medicine is generally pretty conservative. Before AsepticSure, achieving even a 3-log kill of infective pathogens (99.9%) throughout an entire health care room was simply not possible. Most health care professionals already thought they were doing all they could - and all that was necessary. I cannot tell you how many times we have heard, "We are following FDA protocols and using all of the latest cleaning solutions. That is the best we can do."
The resistance to adopting AsepticSure came for two primary reasons. First, the healthcare professionals believed they were doing all they could and second, they probably did not believe AsepticSure truly could achieve a 6-log kill throughout the entire room. After all, no one had ever come remotely close to that. Keep in mind the difference between a 3-log kill and a 6-log kill is a thousand-fold increase! That is a scientific revolution, and revolutionary science takes awhile to be understood, then intellectually accepted, and finally adopted as the new standard.
A big wake up call occurred when our Dr. Michael Shannon discovered in-laboratory that a 5-log control of MRSA plated onto a standard FDA petri dish and then "killed" to 3-log would regenerate to a full 5-log strength again in five days. This expla
Those shares were not bought in the open market. The shares were probably payment for being on the board of directors because MZEI does not have any money in the bank.
Shareholders were diluted again but not much because there are 351mil+ shares outstanding.
The Davita trial is a "safety trial". Only secondarily they will be collecting data. After the 'safety trial" there might be a proof of concept pivotal Phase I/III trial with more inclusive patients.
Look at the inclusion/exclusion requirements of the Davita trial. They are very tough. It may be a reason there is no news that more patients have entered into the trial.